Picture of EKF Diagnostics Holdings logo

EKF — EKF Diagnostics Holdings Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Momentum

Relative Strength (%)
1m-7.09%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-13.02%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Financial Summary

Year End 31st DecUnit201620172018201920202021E2022ECAGR / Avg
Total Revenue£m38.5941.5842.5444.9265.2677.2181.9716.78%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/a+380.82+186.89-25.52+195.33+67.45-3.56n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for EKF

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of EKF Diagnostics Holdings EPS forecast chart

Profile Summary

EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The Company's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240.

Directors

Last Annual
December 31st, 2020
Last Interim
June 30th, 2021
Incorporated
January 7th, 2002
Public Since
June 5th, 2002
No. of Employees
356
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
463,930,564

EKF Share Price Performance

Latest News for EKF

Upcoming Events for EKF

Full Year 2021 EKF Diagnostics Holdings PLC Earnings Release

EKF Diagnostics Holdings PLC Annual Shareholders Meeting

Similar to EKF

Picture of Abingdon Health logo

Abingdon Health

gb flag iconLondon Stock Exchange

Picture of Advanced Medical Solutions logo

Advanced Medical Solutions

gb flag iconLondon Stock Exchange

Picture of Advanced Oncotherapy logo

Advanced Oncotherapy

gb flag iconLondon Stock Exchange

Picture of Angle logo

Angle

gb flag iconLondon Stock Exchange

Picture of Belluscura logo

Belluscura

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email